Li-Fraumeni syndrome & childhood cancer — what the TP53 gene means for your child

Li-Fraumeni syndrome (LFS) is a hereditary condition caused by a change (pathogenic variant) in the TP53 gene — the gene that produces a protein often called the "guardian of the genome." In healthy cells, the TP53 protein detects damaged DNA and either pauses cell growth to allow repairs, or triggers the cell to self-destruct if the damage cannot be fixed. When one copy of the TP53 gene carries a pathogenic variant — inherited from a parent or, in some cases, arising for the first time in the child — this protective mechanism is significantly weakened. Cells with damaged DNA can then continue dividing instead of being corrected or eliminated, raising the risk of tumours forming across multiple body tissues and at a young age. Children and young adults with Li-Fraumeni syndrome face a substantially elevated lifetime risk of developing cancer, and many have an earlier onset than would be expected for those cancers in the general population.

Li-Fraumeni syndrome is associated with a broad range of cancers. In children and adolescents, the tumour types seen most frequently include soft-tissue sarcomas (such as rhabdomyosarcoma), bone cancers (particularly osteosarcoma), brain and central nervous system tumours (including choroid plexus carcinoma — a rare brain tumour that is strongly associated with LFS in young children), and certain types of leukaemia. Adrenocortical carcinoma — a cancer of the adrenal gland that is very uncommon in children generally — occurs at a considerably higher rate in children with LFS, and its occurrence in a young child is often the first clue that LFS may be present. Breast cancer in young women, and other tumour types, can occur in adulthood. A key feature of LFS is that the same person may develop more than one cancer over their lifetime, sometimes decades apart, and that cancers may appear in multiple generations of a family.

Li-Fraumeni syndrome is diagnosed through germline genetic testing — a blood test (or sometimes a saliva sample) that looks for a pathogenic variant in the TP53 gene. Genetic testing may be recommended in several situations: when a child or young adult develops a cancer that is part of the LFS spectrum (particularly an uncommon tumour type such as adrenocortical carcinoma or choroid plexus carcinoma); when a family history suggests multiple cancers across generations at young ages; or when a clinical geneticist applies established criteria and finds that the pattern of cancers in the family is consistent with LFS. Before genetic testing is arranged, families are offered genetic counselling — a consultation with a specialist who explains what the test can and cannot tell you, what a positive or negative result would mean for the child and other family members, and how to make an informed decision about whether to proceed. It is important that genetic testing for LFS is interpreted by an experienced multidisciplinary team, as the implications are wide-ranging.

Yes, in most cases. Li-Fraumeni syndrome follows an autosomal dominant inheritance pattern — a TP53 pathogenic variant in one copy of the gene is sufficient to confer significantly elevated cancer risk. If your child carries such a variant, each biological parent has a meaningful chance of also being a carrier (unless the variant arose de novo — for the first time in your child, without being inherited). If a parent carries the variant, their other children and first-degree relatives may also carry it. Because the implications are serious — and because early surveillance can genuinely make a difference in catching tumours at an earlier stage — cascade testing of relatives is strongly recommended once a variant has been identified in the family. Your child's oncology team and clinical genetics service will guide you through who should be tested and in what order, at a pace that takes your family's emotional readiness into account. You are not alone in navigating this.

Structured, regular surveillance is one of the most important tools for families living with Li-Fraumeni syndrome. The goal of surveillance is to detect any tumour as early as possible — before it has grown large, spread, or caused symptoms — when treatment options are broader and outcomes are generally better. Current international guidelines recommend a comprehensive surveillance protocol for confirmed LFS carriers that includes whole-body MRI scans at regular intervals, brain MRI, abdominal and adrenal ultrasound in young children, and age-appropriate mammographic screening in women. Blood tests and physical examinations are also part of the schedule. Any new symptom — an unexplained lump, persistent pain, neurological change, or fatigue — should always be reported promptly to the care team rather than waiting for the next scheduled visit. Surveillance does not prevent cancer from forming, but it does mean that if a tumour does appear, there is a much better chance of finding it when it is most treatable. Your child's specific surveillance plan will be personalised by their oncology and genetics team.

Hearing the words "TP53 mutation" alongside a cancer diagnosis is understandably alarming. Here are some questions worth asking your child's team. First: is the TP53 change found in the tumour only, or is it also present in normal (germline) cells such as blood? A TP53 change found only in the tumour is a somatic mutation — common in many cancers and not the same as Li-Fraumeni syndrome. A TP53 change present in every cell of the body (germline) is what defines LFS. Second: if LFS is suspected, should my child be referred to a clinical genetics service for formal assessment and counselling? Third: are any changes needed to the treatment plan in light of this finding — for example, minimising radiation exposure where possible, since LFS carriers may have an elevated sensitivity to radiation-induced second tumours? And fourth: what surveillance plan is recommended for my child and which family members should also be tested? Bringing a list of questions to each appointment helps ensure nothing is missed. CION's 45-minute consultations give you the time to work through all of them.